Cargando…
Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations
BACKGROUND: D2C7-IT is a novel immunotoxin (IT) targeting wild-type epidermal growth factor receptor (EGFRwt) and mutant EGFR variant III (EGFRvIII) proteins in glioblastoma. In addition to inherent tumoricidal activity, immunotoxins induce secondary immune responses through the activation of T cell...
Autores principales: | Chandramohan, Vidyalakshmi, Bao, Xuhui, Yu, Xin, Parker, Scott, McDowall, Charlotte, Yu, Yen-Rei, Healy, Patrick, Desjardins, Annick, Gunn, Michael D., Gromeier, Matthias, Nair, Smita K., Pastan, Ira H., Bigner, Darell D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6542114/ https://www.ncbi.nlm.nih.gov/pubmed/31142380 http://dx.doi.org/10.1186/s40425-019-0614-0 |
Ejemplares similares
-
EGFR/EGFRvIII-targeted immunotoxin therapy for the treatment of glioblastomas via convection-enhanced delivery
por: Bao, Xuhui, et al.
Publicado: (2016) -
Antitumor efficacy of D2C7-(scdsFv)-PE38KDEL, a novel immunotoxin targeting EGFRwt and EGFRvIII, by convection-enhanced delivery in orthotopic brain tumor mouse models
por: Bao, Xuhui, et al.
Publicado: (2013) -
SYST-14 D2C7 CAR EFFECTIVELY AND SAFELY TREATS EGFRWT AND EGFRVIII-EXPRESSING TUMORS FOLLOWING INTRACRANIAL ADMINISTRATION
por: Wilkinson, Daniel, et al.
Publicado: (2023) -
Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models
por: Keir, Stephen T., et al.
Publicado: (2018) -
A novel recombinant immunotoxin-based therapy targeting wild-type and mutant EGFR improves survival in murine models of glioblastoma
por: Chandramohan, Vidyalakshmi, et al.
Publicado: (2013)